The Zacks Analyst Blog Highlights: Pfizer, Eli Lilly, Archer Daniels Midland, RadioShack and Sprint

For Immediate Release

Chicago, IL – February 1, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Pfizer ( PFE - Analyst Report), Eli Lilly ( LLY - Analyst Report), Archer Daniels Midland ( ADM - Analyst Report), RadioShack ( RSH - Analyst Report) and Sprint ( S - Analyst Report).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Tuesday’s Analyst Blog:

Earnings Roll Out, EU Makes Progress

There is favorable looking news out of Europe this morning, with Greece appearing to be making progress in arm-twisting its private creditors to accept ‘voluntary’ losses on their holdings and all except two of the 27 European Union members agreeing to put more flesh on their plans to move towards a closer fiscal union.

As a follow up to the December agreement, 25 out of the 27 EU members agreed to new rules that define new deficit and debt levels for member countries and provides for stricter enforcement mechanisms. The two hold-outs -- Britain and the Czech Republic -- are not part of the Euro-zone, which is a sub-set of the broader EU.

The agreement requires governments to keep budget deficits at an average of 0.5% of GDP over the economic cycle and to reduce government debt to 60% of GDP over time. There will be fines for errant governments, with the European Court of Justice given the authority to impose fines, which will be capped at 0.5% of GDP.

The leaders did not announce the creation of a €500 billion permanent bailout fund, known as the European Stability Mechanism. A decision on that issue, including the proposal to boost the size of the fund, has been put off till the next EU summit on March 1. This is an incremental positive development for Europe as it moves the union towards greater fiscal integration.

On the earnings front, Pfizer ( PFE - Analyst Report) came ahead of earnings and revenue expectations, but the company lowered its 2012 earnings guidance. Eli Lilly ( LLY - Analyst Report) also came ahead of expectations. Both drug giants recent lost patent protection on core blockbuster drugs, with Pfizer’s Lipitor and Lilly’s Zyprexa going generic. Archer Daniels Midland ( ADM - Analyst Report) missed earnings expectations on continued margin pressures in its oilseeds business, offsetting its better-than-expected revenue numbers.

RadioShack ( RSH - Analyst Report) pre-announced weaker than expected numbers for the quarter, citing softness in its business reselling Sprint ( S - Analyst Report) wireless service and margin pressures due to greater reliance on promotions during the holiday season.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

Read the full analyst report on PFE

Read the full analyst report on LLY

Read the full analyst report on ADM

Read the full analyst report on RSH

Read the full analyst report on S